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Background: Preterm labor (PTL) is a serious emergency wherein robust management
is imperative for achieving improved outcome.
Objective: To evaluate the efficacy and safety of nifedipine alone vs nifedipine with
vaginal progesterone in managing threatened PTL.
Materials and Methods: This comparative study was carried out at the Pakistan Institute
of Medical Sciences, Islamabad over a 2-year’ period, from September, 2013 to August,
2015. The study included 276 patients with threatened PTL. Half of them were allocated
to nifedipine alone group whereas the remainder half to the additional progesterone
group. In nifedipine alone group (group A), all the patients were given 20 mg of rapid
release nifedipine orally. If uterine contraction continued, a 10 mg dose was repeated
every 20 min with a maximum of 40 mg within the first hour. After completing the first
hour, 20 mg was given every 4–6 hr for 72 hr. In the additional vaginal progesterone
group (group B), following successful tocolysis with nifedipine, additional - maintenance
tocolysis was ensured with vaginal progesterone 200 mg daily.
Results: Successful acute tocolysis was achieved with nifedipine among 86.23%
patients. Mean pregnancy prolongation was 11.13 ± 5.08 days in group A while
29.73 ± 3.10 days in group B. (p ≤ 0.001)
Conclusion: Acute tocolytic therapy with nifedipine was successful in the majority of
our patients. The additional daily use of vaginal progesterone suppositories resulted
in significant prolongation of pregnancy as well as reduction in the rate of low birth
weight and neonatal ICU admissions.
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1. Introduction
As per the definition of the World Health
Organization, Preterm labor (PTL) refers to the
onset of labor after the gestation of viability and
before 37 completed weeks of pregnancy (1, 2).
Compared to the actual PTL, a threatened PTL is
diagnosed when there are documented uterine
contractions without any evidence of cervical
change. Spontaneous PTL and the consequent
delivery account for approximately 50% of the
preterm deliveries (PTDs), which in turn constitute
the predominant causes of perinatal mortality
and morbidity. The incidence of PTL is variably
reported from different parts of the globe and
ranges from 5% to 18% of all births (3–5). PTL
has been a formidable foe for the healthcare
professionals, both in the developing as well as
developed countries. It is widely recognized that
its prevention or effective management has the
potential to improve the neonatal outcome and
reduce the cost of management. A variety of
pharmacological agents have been tested in the
past to relax the uterine myometrium and so inhibit
uterine contractions and stop the threatened PTL.
For instance, nifedipine, magnesium sulphate,
β-receptor agonists, prostaglandin synthase
inhibitors, and oxytocin receptor blockers, etc
(6–9).
The present study was carried out to determine
the efficacy and safety of oral nifedipine
with or without vaginal progesterone in the
management of threatened PTL in terms of
pregnancy prolongation, neonatal outcome and any
maternal side effects of the therapeutic agents
employed.
2. Materials and Methods
This quasi-experimental study was carried out
at the Department of Obstetrics and Gynecology,
Pakistan Institute of Medical Sciences, Islamabad
over a period of two years, from September, 2013
to August, 2015. The study included all those
patients with threatened PTL (i.e., between 24
and 37 completed weeks of gestation) who were
presented with one or more of the following:
(1) Four uterine contractions per 20 min, (2)
Cervical dilatation of 0–3 cm in nulliparous and
1–3 cm in multiparous with intact membranes,
and (3) Changing cervical effacement to 50% as
observed on serial examinations. Exclusion criteria
were patients with cervical dilatation of > 4 cm
and ruptured membranes, non-reassuring fetal
status, intrauterine growth restriction, congenital
anomalies, any known maternal systemic disorders,
and any contraindication to nifedipine therapy.
All patients were admitted for management
indoor. They were assessed initially by detailed
history, thorough examination, and baseline
investigations. Half of the patients were randomly
assigned to nifedipine alone group and the
remaining half were randomized to the additional
progesterone group. Computer generated random
number table was employed for randomization.
The two groups were matched for important
initial demographic and clinical variables. A birth
weight below the 5th percentile was considered
as intrauterine growth restriction. Patients with
gestational age < 34 wk were given intramuscular
injections of 6 mg dexamethasone, repeated every
12 hr for four consecutive doses. Intravenous
injections of amoxicillin 1 g m twice daily for 72 hr
were also given to them.
2.1. The treatment protocol for each
group was as follows
In Nifedipine alone group (group A), all the
patients were given 20 mg of rapid release
nifedipine orally. If uterine contractions continued,
repeat dose of nifedipine capsule of 10 mg
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was given every 20 min. The maximum dose of
nifedipine was limited to 40 mg within the first hour
of starting the tocolytic treatment. Once the first
hour was over, a regular dose of 20 mg nifedipine
was administered every 4–6 hr consecutively for
72 hr. Dosage schedule was modified according to
the patient’s clinical symptoms and vital signs. The
blood pressure was monitored serially every 15 min
to prevent hypotension.
Tocolysis was considered successful if uterine
activity reduced to <4 contractions per hour
with the absence of cervical change. Tocolytic
failure was defined as delivery in <48 hr after
the initiation of the therapeutic agents. Those
with tocolytic failure were excluded from further
analysis. In the additional vaginal progesterone
group (group B), following successful tocolysis with
nifedipine, the patients were treated with additional
maintenance tocolysis with vaginal progesterone
200 mg daily until delivery or the 37th completed wk
of gestation.
The primary outcome measure analyzed
was the prolongation of pregnancy (in terms
of delivery delayed by 48hr following acute
tocolysis with nifedipine, delivery before 34
and 37 wk with maintenance tocolysis with
vaginal progesterone). The secondary outcome
measures included the neonatal outcome and any
maternal side effects with the therapeutic agents
employed.
2.2. Ethical consideration
The study protocol was approved by the hospital
ethics committee (HEC) and written informed con-
sent was taken from all the participating patients.
Anonymity of the participants was ensured.
2.3. Statistical analysis
The data were recorded on the proforma
and subjected to statistical analysis, using
SPSS software (Statistical package for social
sciences, Version 17.0, Chicago, IL, USA). The
percentages of various outcome variables
were compared by employing chi-square test
and p ≤ 0.05 was regarded as statistically
significant.
3. Results
3.1. Demographic characteristics of the
included patients
There were a total of 276 patients, with
138 patients in either group. There was no
significant difference in the baseline maternal
demographics and clinical characteristics of the
two groups. The age of the patients ranged
between 16 and 45 yr with a mean age of
23.03 ± 8.35 yr in group A and 23.16 ± 8.37 yr in
group B. Majority of the patients (n = 208; 75.36%)
presenting with threatened PTL were below 25 yr
of age.
3.2. Presenting clinical features among
the patients
Most of the patients (n = 263; 95.28%) were
presented to the emergency department while
the remaining (n = 13;4.71%) were presented to
the outpatient department. The gestational age
at presentation varied from 24 to 36 wk
with a mean of 32.01 ± 1.92 wk in group A
while 32.07 ± 1.81 wkin group B. The minimum
gestational age at study entry was 24 wk and
the maximum age was 36 wk.The important
presenting clinical features such as the maternal
age (yr), gestational age at presentation (wk),
duration of the present threatened PTL, gravidity
status (primigravida versus multigravida), singleton
versus twin pregnancy, past history of PTL,
past history of abortion are all summarized in
Table I.
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3.3. Pregnancy outcome data
Successful acute tocolysis with nifedipine was
achieved in 86.23% of the initially recruited patients.
There was significant prolongation of pregnancy/
the mean time of delivery postponement in the
group B as compared to the group A. Mean
pregnancy prolongation was 11.13 ± 5.08 days in
group A and 29.73 ± 3.10 days in group B. (p = 0.002)
(Table II).
3.4. Neonatal outcomes data
Table III shows the comparison of various
neonatal outcome measures between the two689
groups of patients. The number of neonates
admitted in neonatal intensive care unit and rate
of Low birth weight were significantly less in
group B than group A. (p = 0.002 and p ≤ 0.001
respectively). There was no case of intrauterine
death.
3.5. Maternal side effects of nifedipine
Hypotension 52(18.70%) and tachycardia
20(7.19%) were the commonest side effects
observed with nifedipine therapy. There
was no case of serious side effects that
warranted discontinuation of the therapy
(Table IV).
Table I. The presenting features among the included patients (n = 138 each group)
Parameters Group A Group B
Maternal age∗ 23.03 ± 8.35 23.16 ± 8.37
Initial gestational age∗ 32.01 ± 1.92 32.07 ± 1.81
Duration of the present PTL∗ 6.57 ± 5.62 6.77 ± 5.90
Gravidity status (primigravida versus multigravida 113/25 112/26
Singleton versus twin pregnancy 127/11 126/12
Past PTL history∗∗ 17 (12.31) 16 (11.59)
Past history of abortion∗∗ 7 (5.07) 6 (4.34)
∗Data presented as mean ± SD
∗∗Data presented as n (%)
The two groups were matched with respect to the baseline maternal demographics and clinical characteristics
PTL: Preterm labor
Table II. The pregnancy outcome measures (n = 138 each group)
Parameters Group A Group B P-value
Time of postponing delivery (days) 11.13 ± 5.08 29.73 ± 3.10 ≤0.001∗a
Preterm birth before 34 weeks∗∗ 14(10.14) 8(5.79) 0.50∗∗b
Preterm birth before 37 weeks∗∗ 73(52.89) 49(35.50) ≤0.001∗a
∗Data presented as mean ± SD
∗∗Data presented as n (%)
∗a: p-value < 0.05 Significant
∗∗b: p-value > 0.05 Insignificant
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Table III. The neonatal outcome measures (n = 138 each group)
Parameters Group A Group B P-value
Number of neonatal deaths 13 (9.42) 3 (2.17) 0.30∗∗
LBW (Kg) 73 (52.89) 31 (22.46) 0.00∗
RDS 19 (13.76) 9 (6.52) 0.50∗∗
Number of neonates admitted in NICU 31 (22.46) 7 (5.07) 0.00∗
Apgar score <7 9 (6.52) 2 (1.44) 0.53∗∗
Intra cranial bleeding 3 (2.17) - 1.00∗∗
Sepsis 7 (5.07) 2 (1.44) 0.67∗∗
Data presented as n (%); p-value < 0.05 Significant; p-value > 0.05 Insignificant
NICU: Neonatal intensive care unit; LBW: Low birth weight; RDS: Respiratory distress syndrome
Table IV. The maternal side effects observed with nifedipine treatment (n = 138 each group)
Parameters Group A Group B
Tachycardia 11 (7.97) 9 (6.52)
Hypotension 25 (18.11) 27 (19.56)
Headache 9 (6.52) 11 (7.97)
Hot flushes 5 (3.62) 2 (1.44)
Nausea/ vomiting 2 (1.44) 0
Data presented as n (%)
There were no case of serious side effects that warranted discontinuation of the therapy
4. Discussion
In the present study, threatened PTL was more
commonly observed among women of younger
age groups (i.e. below 25 yrof age; 75.36%).
Majority of them wereprimigravida (n = 225; 81.52%).
Our findings are similar to those reported by
Ragunath and co-worker (10) from India, Klauser
and co-worker (11) and Sharami and co-worker
(12) from Iran. In the present study the mean
gestational age at presentation was 32.01 ± 1.92 wk
in group A and 32.07 ± 1.81 in group B patients.
The mean gestational ages reported by Moramezi
and co-worker (7), Sharami and co-worker (12),
Gargari and co-worker (13) and Kashanian and
co-worker (14) were 32 ± 3 wk, 33.95 ± 1.49 wk,
32.2 ± 2.8 wk and 30.8 ± 2.5 wk respectively. In our
study we employed nifedipine for acute tocolysis
as this medication is considered as the first-line
tocolytic agent for the management of threatened
PTL, given its established superiority over β-2
receptors agonists and magnesium sulfate. The
tocolytic agentsdonot directly improve the neonatal
outcomes. They rather delay the preterm delivery
and thus provide an opportunity to administer
corticosteroids to the mother and also ensure her
transportation to a tertiary care facility for better
neonatal care after delivery. In premature neonates,
antenatal corticosteroids reduce morbidity and
mortality. Tocolytic therapy therefore holds the
potential to improve outcomes from preterm
delivery in these cases. The preterm babies (born
between 20 and 36 completed weeks of gestation)
are generally more prone to be ill and are less
likely to survive than babies born at term. The
earlier these babies are born the more likely they
are to have problems particularly because of their
lung immaturity. The use of nifedipine reduces
the risk of delivery within 7 days of initiation of
treatment and delivery before 34 wk of gestation.
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This in turn helps to improve clinically important
neonatal outcomes. For instance, respiratory
distress syndrome, intraventricular hemorrhage,
necrotizingenterocolitis, and neonatal jaundice
(1–4, 14).
In the present study, successful acute tocolysis
with nifedipine was achieved in 86.23% of the
initially recruited patients. Nifedipine successfully
suppressed threatened labor when dilatation was
less than 1.5 cm and effacement less than 50%. The
mean prolongation of pregnancy was 11.13 ± 5.08
days with nifedipine alone in the present study.
Our findings conform to several reported studies
on the use of nifedipine for acute tocolysis
(10, 11, 14). Hypotension and tachycardia were
the most common side effects observed with
nifedipine in our study. The published literature
has documented a variety of occasional serious
adverse effects with nifedipine therapy. For
instance, myocardial infarction, severe maternal
dyspnea, pulmonary edema, maternal hypoxia,
severe maternal hypotension with fetal death, and
atrial fibrillation. A case series study reported that
six out of seven cases of nifedipine-associated
severe maternal dyspnea occurred in women with
twin pregnancies and recommended to exercise
caution when using nifedipine among patients with
compromised cardiovascular function. The overall
incidence of serious adverse effects reported with
the use of nifedipine is ≤1%. Nifedipine does not
have effects on fetal and neonatal death(10, 15–17).
In our study the use of additional vaginal
progesterone after successful tocolysis with
nifedipine resulted in significant prolongation
of pregnancy. It also resulted in reducing
neonatal ICU admissions as well as the rate of
LBW among the neonates. The importance of
progesterone in maintaining pregnancy has long
been recognized. Progesterone is a multifaceted
hormone which has several crucial functions
during pregnancy. For instance, it supports uterine
quiescence, suppresses contractile genes and
prevents the rejection of the fetus by the mother
through suppressing the cellular component
of the immune system. Despite the apparent
benefits of progesterone in high-risk populations,
progesterone has largely been studied only as a
prophylactic method in asymptomatic women, not
as a tocolytic agent in women with symptoms of
threatened PTL. One study has shown that patients
who remained undelivered after an episode of
PTL underwent progressive cervical shortening
during the three-week observational period and
treatment with a high-dose progesterone was
associated with both a lower cervical shortening
as well as a reduced rate of PTB. Our finding
of the positive effects of vaginal progesterone
on significantly prolonged pregnancy conforms to
several published studies from different parts of the
world (12, 13, 18–20).
4.1. Strengths and limitations of the
study
Our study has certain strengths as well as
suffers some limitations. The major strength of
the present study is that it was a well-designed
quasi-experimental study performed for the first
time in an institution in Pakistan. Second strength of
this study is its apparent external validity, supported
by the fact that our primary results are consistent
with those of similar trials. Third strength of the
study is the diverse nature of the Pakistani patient
population presenting with variable demographic
features. One limitation of the current study is
that the primary endpoint (i.e. prolongation of
pregnancy) was a surrogate for several neonatal
outcomes. Secondly our case volume was not
large enough to carry out in-depth analyses of
the risk factors for various outcomes measures
under scrutiny. Thirdly our study was limited to a
single institution. Additionally there was no blinding
or use of any placebo in the study to decrease
any potential bias. Future well-designed local
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multicenter studies are recommended to improve
upon the limitations of the present study.
5. Conclusion
Acute tocolytic therapy with nifedipine was
successful in the majority of our patients without
any serious untoward effects that warranted
discontinuation of the medication. The additional
daily use of vaginal progesterone suppositories
of 200 mg (following successful acute tocolysis)
was associated with a significant prolongation of
pregnancy as well as significant reduction in the
rate of LBW and neonatal ICU admissions.
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